A new pathogenetic treatment for symptomatic diabetic polyneuropathy? Andrew J. M. Boulton Clinical Trials Report 29 November 2009 Pages: 413 - 414
Early administration of enalapril and losartan to patients with type 1 diabetes Robert C. Stanton Clinical Trials Report 29 November 2009 Pages: 415 - 416
Controversies in off-loading: Should big brother be watching? Ryan T. CrewsFrank L. BowlingAndrew J. M. Boulton Current Reports / Diabetes / Invited Commentary 29 November 2009 Pages: 417 - 419
Not all neuropathy in diabetes is of diabetic etiology: Differential diagnosis of diabetic neuropathy Roy Freeman OriginalPaper 29 November 2009 Pages: 423 - 431
The Eurodiab study: What has this taught us about diabetic peripheral neuropathy? Solomon TesfayeDinesh Selvarajah OriginalPaper 29 November 2009 Pages: 432 - 434
The prevalence of diabetic neuropathy according to ethnicity Jay M. Sosenko OriginalPaper 29 November 2009 Pages: 435 - 439
MRSA and diabetic foot wounds: Contaminating or infecting organisms? Frank L. BowlingEdward B. JudeAndrew J. M. Boulton OriginalPaper 29 November 2009 Pages: 440 - 444
What is the role of renin inhibition in the treatment of diabetic kidney disease? Radko Komers OriginalPaper 29 November 2009 Pages: 447 - 452
Aldosterone and diabetic kidney disease Young Sun KangDae Ryong Cha OriginalPaper 29 November 2009 Pages: 453 - 459
The growing economic burden of diabetic kidney disease Robert N. FoleyAllan J. Collins OriginalPaper 29 November 2009 Pages: 460 - 465
Management of diabetes in dialysis patients Mark E. Williams OriginalPaper 29 November 2009 Pages: 466 - 472
The natural progression of kidney injury in young type 1 diabetic patients Julia M. Steinke OriginalPaper 29 November 2009 Pages: 473 - 479
